Our management and strategy consulting firm was founded in November 2008, which was clearly a difficult period for the U.S. economy and a year that many investors would like to forget. The Dow Jones Industrial average recorded its worst annual performance since 1931 and the NASDAQ Composite had its worst year since inception in 1971. [...] read more..
Showing posts with label Strategy. Show all posts
Showing posts with label Strategy. Show all posts
Sunday, 17 June 2012
Dow Jones Industrial Average-Strategy Consulting-Difficult Period-Bear Market
Bear Market Advice and Perspectives
source:http://lifesciencedigest.com
Tuesday, 20 March 2012
The European Association Of Urology-Prostate Cancer
The challenge of prostate cancer drug approval versus reimbursement
Here at the European Association of Urology (EAU) congress in Paris, there are some interesting debates amongst delegates attending the meeting regarding new therapies either recently – or about to be approved – for castrate-resistant prostate cancer (CRPC). For example: … Continue reading ? read more..
Labels:
Abiraterone,
Alpharadin,
Cabazitaxel,
Chemotherapy,
Docetaxel,
Eau12,
EMA,
European Association Of Urology,
MDV3100,
New Products,
NICE,
Pipeline,
Politics,
Prostate Cancer,
Provenge,
Random Musings,
Reimbursement,
Strategy,
Targeted Therapies,
The European Association Of Urology
Monday, 19 March 2012
Cancer News-News Wires-Research
J&J unblind Zytiga phase 3 trial in pre-chemotherapy castrate-resistant prostate cancer
The big cancer news that hit the news wires this morning was not entirely surprising: “Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA (abiraterone acetate) plus prednisone for the treatment of … Continue reading ? read more..
Labels:
Abiraterone,
Cancer News,
Castrate-Resistant Prostate Cancer,
Chemotherapy,
CRPC,
Market Trends,
MDV3100,
New Products,
News,
News Wires,
Orteronel,
Pipeline,
Pre-Chemotherapy,
Prostate Cancer,
Provenge,
Research,
Strategy,
TAK-700,
Targeted Therapies,
Zytiga
Subscribe to:
Posts (Atom)